The Latest Cardiac and Vascular News
MINNEAPOLIS, March 16, 2021 /PRNewswire/ — Imbio, a leading provider of artificial intelligence (AI) solutions for medical imaging analysis, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its RV/LV Analysis™ algorithm. The RV/LV Analysis algorithm is a rapid, automated assessment of potential right ventricular dilation. The tool quickly and accurately measures the […]
CHENNAI, India, March 16, 2021 /PRNewswire/ — The Apollo Hospitals group, one of Asia’s largest and most trusted healthcare group, notched up a record milestone with the successful completion of four consecutive MitraClip procedures in one day. The MitraClip implants were carried out on four patients suffering from severe heart failure on the same […]
New subsidiary will further the Company’s research into treating COVID-related heart muscle injury. A patent has been filed for a therapy to ameliorate and potentially repair myocardial damage. NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Healthtech Solutions, Inc. (OTC: HLTT) (the “Company”), parent company of Medi-Scan, Inc., today […]
2,400-Patient Trial Utilizes Globally-Respected SWEDEHEART Registry Database in Randomized Study of First Metallic Device Treating Coronary Artery Disease That Adapts to Vessel Physiology MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced commencement of the INFINITY-SWEDEHEART randomized controlled trial (RCT) of the DynamX™ Coronary Bioadaptor System, the […]
SECAUCUS, N.J. and HELSINKI, March 15, 2021 /PRNewswire/ — Zora Biosciences Oy, a clinical diagnostics company whose mission is to identify robust markers of disease and develop them into high-throughput, health-economic value-added clinical methods, today announced it has signed a non-exclusive license agreement with Quest Diagnostics (NYSE: DGX), the world leader in diagnostic information services, […]
LAVAL, Quebec–(BUSINESS WIRE)–Altasciences is proud to have conducted preclinical studies for Verve Therapeutics that support the development and advancement of Verve’s gene editing approach to treating cardiovascular diseases. Altasciences’ Seattle team performed intravenous preclinical studies, including supporting analyses of pharmacodynamic markers and whole liver DNA editing, in non-human primates, that show […]
New educational app from the leading cardiopulmonary digital health company offers clinical screening resources and real world application on identifying heart and lung abnormalities OAKLAND, Calif., March 11, 2021 (GLOBE NEWSWIRE) — Eko, a cardiopulmonary digital health company, today announced the launch of its clinical education initiative. Eko Academy, a free […]
MIAMI, March 11, 2021 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the U.S. Food & Drug Administration (FDA) has granted expanded access approval for the administration of Longeveron’s investigational cell […]
– Published in the New England Journal of Medicine (NEJM), the REDUCE Study continues to show the largest reduction in recurrent ischemic stroke in all PFO shunt sizes over medical therapy alone.*,¹ – Long-term results highlight GORE® CARDIOFORM Septal Occluder can be trusted for patient safety and effective defect closure. FLAGSTAFF, Ariz., March […]
CHENGDU, China–(BUSINESS WIRE)–Lipigon Pharmaceuticals AB (”Lipigon”), developer of therapeutics for lipid-related diseases, today announced that the company has expanded its agreement with the Shanghai STAR listed company HitGen Inc. (”HitGen”) to include a second novel target. With joint efforts, the aim is to develop a treatment for cardiometabolic disease. Lipigon […]
